Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of TAS-106 in Patients With Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy

NCT00737360 is registered in ClinicalTrials.gov with Taiho Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT00737360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00737360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of TAS-106 in Patients With Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2008
Completion date
February 29, 2012
Enrollment
27 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer